Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor α-neutralising treatments in rheumatoid arthritis

Background:Macrophage migration inhibitory factor (MIF) is an inflammatory mediator associated with RA severity. In various diseases, MIF polymorphisms are associated with clinical response glucocorticoid (GC) treatment. It is unclear whether MIF polymorphisms determine GC response in rheumatoid art...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of the rheumatic diseases 2007-11, Vol.66 (11), p.1525-1530
Hauptverfasser:	Radstake, Timothy R D J, Fransen, Jaap, Toonen, Erik J M, Coenen, Marieke J H, Eijsbouts, Agnes E, Donn, Rachelle, van den Hoogen, Frank H J, van Riel, Piet L C M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal - therapeutic use Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - genetics Cohort Studies Extended Report Female glucocorticoids Glucocorticoids - therapeutic use Humans Infliximab macrophage inhibitory factor Macrophage Migration-Inhibitory Factors - genetics Male Middle Aged Phenotype Polymorphism, Genetic Prognosis Registries rheumatoid arthritis Severity of Illness Index Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!